All In Biotech

Drug Trial Radar · NCT06246071

A Study of TYK-00540 in Adult Patients With Solid Tumors

A Phase Ia/Ib, Multicenter, Open-label Study of TYK-00540, Administered Orally in Adult Patients With Locally Advanced/Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Feb 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

Jan 2, 2024

Primary completion

Dec 5, 2026

Study completion Dec 5, 2026

Sponsor

Lead sponsor
TYK Medicines, IncIndustry
Sponsor type
Industry
First posted
Feb 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the safety and tolerability of TYK-00540, with dose-escalation stage and dose-expansion stage.

Conditions

  • Locally Advanced or Metastatic Solid Tumors

Interventions

  • TYK-00540Drug

    TYK-00540 PO, BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicity (DLT)Time frame: Within 31 days of the first dose
  2. Recommended dose for combination-agent escalation and single-agent expansion (RDE)Time frame: 1 year
  3. Adverse events (AEs)Time frame: From Baseline up to 28 days after the end of the treatment
  4. Objective response rate (ORR)Time frame: At least 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Hefei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.